Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Paroxetine in child and adolescent outpatients with panic disorder
Autore:
Masi, G; Toni, C; Mucci, M; Millepiedi, S; Mata, B; Perugi, G;
Indirizzi:
Univ Pisa, Div Child Neurol & Psychiat, I-56018 Calambrone, PI, Italy UnivPisa Calambrone PI Italy I-56018 hiat, I-56018 Calambrone, PI, Italy IRCCS Stella Maris, Pisa, Italy IRCCS Stella Maris Pisa ItalyIRCCS Stella Maris, Pisa, Italy Univ Pisa, Dept Psychiat, I-56100 Pisa, Italy Univ Pisa Pisa Italy I-56100 iv Pisa, Dept Psychiat, I-56100 Pisa, Italy
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 11, anno: 2001,
pagine: 151 - 157
SICI:
1044-5463(200122)11:2<151:PICAAO>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; PSYCHIATRIC-DISORDERS; REFERRED CHILDREN; DOUBLE-BLIND; PLACEBO; EPIDEMIOLOGY; AGORAPHOBIA; COMORBIDITY; PREVALENCE; ATTACKS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Masi, G Univ Pisa, Div Child Neurol & Psychiat, Via Giacinti 2, I-56018 Calambrone, PI, Italy Univ Pisa Via Giacinti 2 Calambrone PI Italy I-56018 ne, PI, Italy
Citazione:
G. Masi et al., "Paroxetine in child and adolescent outpatients with panic disorder", J CH AD PSY, 11(2), 2001, pp. 151-157

Abstract

Paroxetine has repeatedly been shown to be effective in the treatment of panic disorder (PD) in adults, and, according to previous case observations,it may be useful in treating children and adolescents with PD as well. This preliminary naturalistic study examines effectiveness and safety of paroxetine in the treatment of children and adolescents with PD. A chart review was conducted on 18 patients with Diagnostic and Statistical Manual of Mental Disorders PD admitted to the Division of Child Neurology and Psychiatry and to the Department of Psychiatry at the University of Pisa. Paroxetine was given at an initial mean dosage of 8.9 +/- 2.1 mg/day and was gradually increased up to 40 mg/day, depending on clinical response and side effects. Clinical status was assessed with the Clinical Global Impression (CGI) andadverse effects were assessed retrospectively at each visit. Patients withfinal CGI-Improvement scores of 1 or 2 were considered responders. Mean paroxetine treatment duration was 11.7 +/- 8.3 months, with a mean final dosage of 23.9 +/- 9.8 mg/day (range, 10-40 mg/day). No patient had to interrupt the treatment because of side effects. Fifteen patients (83.3%) were considered responders. The mean change on the CGI-Severity scale was statistically significant (p<0.0001). Paroxetine was well tolerated and effective in the treatment of PD in these children and adolescents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 01:09:41